Corient Private Wealth LLC trimmed its holdings in shares of DaVita Inc. (NYSE:DVA - Free Report) by 5.6% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 34,844 shares of the company's stock after selling 2,075 shares during the period. Corient Private Wealth LLC's holdings in DaVita were worth $5,211,000 as of its most recent SEC filing.
Other institutional investors have also recently modified their holdings of the company. JPMorgan Chase & Co. raised its holdings in shares of DaVita by 17.8% in the third quarter. JPMorgan Chase & Co. now owns 609,076 shares of the company's stock worth $99,846,000 after acquiring an additional 92,014 shares during the last quarter. Amundi lifted its holdings in DaVita by 116.4% in the 4th quarter. Amundi now owns 446,386 shares of the company's stock valued at $68,726,000 after purchasing an additional 240,126 shares in the last quarter. KBC Group NV boosted its stake in shares of DaVita by 0.8% during the 4th quarter. KBC Group NV now owns 316,155 shares of the company's stock worth $47,281,000 after purchasing an additional 2,636 shares during the last quarter. BNP Paribas Financial Markets grew its holdings in shares of DaVita by 23.9% during the third quarter. BNP Paribas Financial Markets now owns 292,039 shares of the company's stock worth $47,874,000 after buying an additional 56,389 shares in the last quarter. Finally, Nordea Investment Management AB lifted its stake in shares of DaVita by 4.9% during the fourth quarter. Nordea Investment Management AB now owns 264,535 shares of the company's stock valued at $39,712,000 after buying an additional 12,339 shares during the period. 90.12% of the stock is currently owned by institutional investors and hedge funds.
Analyst Upgrades and Downgrades
DVA has been the subject of several recent analyst reports. Cowen reaffirmed a "hold" rating on shares of DaVita in a research note on Tuesday, February 18th. Barclays lifted their price objective on DaVita from $164.00 to $169.00 and gave the company an "equal weight" rating in a research report on Tuesday, February 18th. Sanford C. Bernstein set a $184.00 target price on DaVita in a research report on Friday, February 21st. Finally, StockNews.com cut DaVita from a "buy" rating to a "hold" rating in a report on Friday, March 21st. One analyst has rated the stock with a sell rating, five have assigned a hold rating and one has assigned a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Hold" and a consensus price target of $166.33.
Get Our Latest Research Report on DaVita
DaVita Trading Up 0.3 %
DaVita stock traded up $0.52 during midday trading on Wednesday, reaching $151.30. The stock had a trading volume of 574,022 shares, compared to its average volume of 783,522. The stock's 50-day simple moving average is $158.18 and its 200 day simple moving average is $157.57. DaVita Inc. has a twelve month low of $125.64 and a twelve month high of $179.60. The company has a debt-to-equity ratio of 23.18, a quick ratio of 1.21 and a current ratio of 1.26. The stock has a market capitalization of $12.10 billion, a PE ratio of 14.09, a price-to-earnings-growth ratio of 1.07 and a beta of 0.99.
DaVita (NYSE:DVA - Get Free Report) last released its quarterly earnings data on Thursday, February 13th. The company reported $2.24 earnings per share for the quarter, beating the consensus estimate of $2.14 by $0.10. DaVita had a return on equity of 115.48% and a net margin of 7.31%. Analysts expect that DaVita Inc. will post 10.76 EPS for the current year.
About DaVita
(
Free Report)
DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.
See Also
Before you consider DaVita, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DaVita wasn't on the list.
While DaVita currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
